Sponsor Overview
Explore verified public information about Theriva Biologics SL's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 1 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“Theriva Biologics, is dedicated to developing innovative treatments for patients with cancer. We have developed this Expanded Access Policy to provide a pathway for patients who may benefit from treatment with our investigational product VCN-01 outside of clinical trials.”
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria Purpose: Theriva Biologics, is dedicated to developing innovative treatments for patients with cancer. We have developed this Expanded Access Policy to provide a pathway for patients who may benefit from treatment with our investigational product VCN-01 outside of clinical trials. As provided by the 21st Century Cures Act, we may revise this policy at any time. Criteria for Expanded Access: Process for Access: Limitations: Contact Information: For more information on our Expanded Access Policy or to request access to our oncolytic adenovirus therapy, please contact our medical team at medicalmonitor@therivabio.com . Approval: This Expanded Access Policy has been approved by our Company’s executive team and will be reviewed periodically to ensure compliance with regulatory requirements and ethical standards. Available Therapies via Single-Patient EA VCN-01
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.